Efficacy of Red Blood Cell Exchange as Adjunctive Treatment for Hypoxemia and Survival Rate of Patients With Severe Coronavirus-2 Disease: An Open-Labeled Phase 2 Randomized Clinical Trial.

Aminianfar, Mohammad; Soleiman-Meigooni, Saeed; Hamidi-Farahani, Ramin; Darvishi, Mohammad; Hoseini-Shokouh, Seyyed Javad; Asgari, Ali; Faraji-Hormozi, Syrous; Asli, Maryam

Aminianfar, Mohammad; Soleiman-Meigooni, Saeed; Hamidi-Farahani, Ramin; Darvishi, Mohammad; Hoseini-Shokouh, Seyyed Javad; Asgari, Ali; Faraji-Hormozi, Syrous; Asli, Maryam.

Affiliation

Aminianfar M; Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Soleiman-Meigooni S; Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Hamidi-Farahani R; Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Darvishi M; Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Hoseini-Shokouh SJ; Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Asgari A; Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Faraji-Hormozi S; Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Asli M; Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.

Front Med (Lausanne) ; 9: 899593, 2022.

Article de En | MEDLINE | ID: mdl-35872770

Mots clés

COVID-19; RBCs exchange; adjunctive treatment; hypoxemia; survival rate (SR)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Clinical_trials Aspects: Ethics Langue: En Journal: Front Med (Lausanne) Année: 2022 Type de document: Article Pays d'affiliation: Iran

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google